Current opinion favors the existence of two major glioma groups: IDH-mutant gliomas, that are typically grade II and III tumors with a relatively favorable prognosis and IDH-WT tumors with a worse prognosis. The gene discussed is IDH1; the disease is central nervous system cancer.